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Abstract
Schimke immuno-osseous dysplasia (SIOD) is a rare multisystem disorder with early mortal-
ity and steroid-resistant nephrotic syndrome (SRNS) progressing to end-stage kidney
disease. We hypothesized that next-generation gene panel sequencing may unsurface oli-
gosymptomatic cases of SIOD with potentially milder disease courses. We analyzed the
renal and extrarenal phenotypic spectrum and genotype-phenotype associations in 34
patients from 28 families, the largest SMARCAL1-associated nephropathy cohort to date.
In 11 patients the diagnosis was made unsuspectedly through SRNS gene panel testing.
Renal disease first manifested at median age 4.5 yrs, with focal segmental glmerulosclerosis
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or minimal change nephropathy on biopsy and rapid progression to end-stage kidney dis-
ease (ESKD) at median age 8.7 yrs. Whereas patients diagnosed by phenotype more fre-
quently developed severe extrarenal complications (cerebral ischemic events, septicemia)
and were more likely to die before age 10 years than patients identified by SRNS-gene panel
screening (88 vs. 40%), the subgroups did not differ with respect to age at proteinuria onset
and progression to ESKD. Also, 10 of 11 children diagnosed unsuspectedly by Next Genera-
tion Sequencing were small at diagnosis and all showed progressive growth failure. Severe
phenotypes were usually associated with biallelic truncating mutations and milder pheno-
types with biallelic missense mutations. However, no genotype-phenotype correlation was
observed for the renal disease course. In conclusion, while short stature is a reliable clue to
SIOD in children with SRNS, other systemic features are highly variable. Our findings sup-
port routine SMARCAL1 testing also in non-syndromic SRNS.
Introduction
Schimke immuno-osseous dysplasia (SIOD; MIM #242900) is an autosomal recessive disorder
characterized by the combination of a progressive proteinuric glomerulopathy with spondy-
loepiphyseal dysplasia, growth retardation, peculiar dysmorphic features (S1 Fig), episodic
lymphopenia, defective cellular immunity, and abnormal skin pigmentation consisting of mul-
tiple lentigines. Cerebral infarcts, thrombocytopenia and microdontia are observed less fre-
quently [1]. Early death is common and mainly related to opportunistic infections secondary
to deficient T cell function. Therapy is largely limited to the prophylaxis and management of
the various disease manifestations, such as dialysis and renal transplantation, supplementation
of hematopoietic growth factors for neutropenia, orthopedic surgery as required, preventive
antiviral therapies and vaccinations, anticoagulation, immunosuppressive therapy for those
with autoimmune manifestations, and thyroid hormone supplementation [1].
The disease is caused by biallelic mutations in the SMARCAL1 gene, encoding the SWI/
SNF-related, matrix-associated, actin-dependent regulator of chromatin subfamily A-like pro-
tein-1 (SMARCAL-1) from the SWI2/SNF2 family of ATP-dependent chromatin remodeling
proteins [2]. Proteins of this family share a conserved helicase ATPase domain comprising an
ATP binding site and a catalytic site for ATP hydrolysis, and use energy from DNA-activated
ATP hydrolysis for DNA remodeling. SMARCAL1 interacts specifically with branched DNA
structures such as replication forks and is thereby critical to the stability of DNA replication
[3]. The precise cellular mechanisms how replication fork malfunctioning leads to the specific
phenotype of SIOD are still elusive.
SIOD has been classified as extremely rare (orphan) disease with an estimated prevalence of
less than 1 per million. We hypothesized that with the advent of comprehensive gene panel
screening more cases with less severe, largely renal-limited phenotypes may be detected.
Material and methods
The PodoNet registry is an international web-based clinical registry (www.podonet.org) for
primary SRNS, congenital nephrotic syndrome or persistent subnephrotic proteinuria with
likely genetic disease. The registry study protocol and characterisation of the PodoNet cohort
were recently published [4].
SMARCAL1-related glomerulopathy
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SMARCAL1 screening was performed either through direct Sanger sequencing of the entire
coding gene sequence and ~20 nucleotides of the adjacent intronic regions (“phenotypic
cases”) or using custom targeted amplicon-based multi-gene NGS panel (Multiplicom, Niel,
Belgium) for FSGS and related glomerulopathies (“incidental cases”). High-throughput
sequencing was performed using the MiSeq/ HiSeq platform (Illumina, San Diego, CA, USA).
All NGS findings were verified by Sanger sequencing, which was also used to test eligible fam-
ily members. For compound heterozygotes, the presence of mutation in trans was confirmed
through parental segregation.
The analysis of structural information for SMARCAL1 protein was performed using Swiss-
Model homology modeling server [5] (https://swissmodel.expasy.org/repository/uniprot/
Q9NZC9, last accessed January 3rd, 2017), S1 File. The in-silico assessment of the effects of the
detected novel variants on protein structure and function was based on several online predic-
tion tools, namely PolyPhen2 (http://genetics.bwh.harvard.edu/pph2/), SIFT (PROVEAN)
(http://sift.jcvi.org/) and Mutation Taster (http://www.mutationtaster.org/). The effect of the
detected mutations on pre-mRNA splicing was performed using Human Splicing Finder 3.0
(http://www.umd.be/HSF3/) to estimate possible alterations in either exonic splicing enhancer
or the splice site acceptor/donor motifs.
Detailed clinical information on renal and extrarenal symptoms was obtained on all SIOD
patients by way of a standardized questionnaire. For comparison, detailed clinical information
from patient cohort with SRNS due to NPHS2-associated glomerulopathy (n = 156) was
extracted from the PodoNet Registry [4].
Frequencies were compared using chi-squared tests with continuity corrections or Fisher
exact test with Freeman-Halton extension for 2x3 tables when applicable. For continuous vari-
ables, differences between groups were evaluated using Kruskal-Wallis test for global and
Mann-Whitney U tests for pairwise comparisons. Patient and renal survival rates were calcu-
lated using Kaplan Meier lifetable analysis. Due to the exploratory character of the analysis, no
adjustment for multiple comparisons was done. Statistical analyses were performed using
STATISTICA 12 (StatSoft; Tulsa, OK, USA) and SAS 9.4 (SAS Institute; Cary, NC, USA) data
analysis software systems.
All patients and/or their legal guardians (if applicable) gave written informed consent and
the study was approved by the local ethics committees.
Results
Study cohort
1105 cases of steroid resistant nephrotic syndrome (SRNS) from pediatric nephrology clinical
centers in European and Middle East countries enrolled through the PodoNet SRNS Registry
[4], and the in-house biobanks at Necker Hospital in Paris, France, Medical University of
Gdańsk, Poland and Hacettepe University Nephrogenetics Laboratory, Ankara, Turkey were
systematically screened as part of SRNS-related gene panel analysis, including 308 patients
negative for mutations in the first-line SRNS-associated genes (NPHS2, exons 8–9 of WT1).
SMARCAL1 mutations were found in 9 patients (0.8%) from mostly consanguineous families.
In two families the mutation was found in a further affected sibling. The observed prevalence
is identical to the one provided in a recent review of 1783 SRNS families who underwent
genetic screening [6].
Moreover, information on 23 patients diagnosed with SIOD based on phenotype evaluation
followed by Sanger testing was included in the analysis, yielding a cohort of 34 patients. SMAR-
CAL1-positive patients did not cluster to any specific region, country or era. Six patients were
SMARCAL1-related glomerulopathy
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previously published; updated long-term follow-up data were obtained from these patients
[7–11].
SMARCAL1 mutation screening
Mutational analysis revealed thirteen novel sequence variants including one large deletion
encompassing the entire gene sequence and fifteen previously reported mutations (Fig 1), with
half of patients being compound heterozygous. Most of the mutations were located in the heli-
case C-terminal subdomain, with a hot-spot region in exon 16 (15 patients had at least one
mutation there). The analysis of structural information for SMARCAL1 protein along with in-
silico assessment of the effects of the mutations on protein structure and function using several
online prediction tools classified novel variants as highly likely to be pathogenic. Detailed bio-
informatic information on the variants is given in S1 File.
The most common mutation in the cohort was c.2542G>T (p.Glu848), present in ten
patients from eight families of Central-European descent (Polish, Czech, German). This vari-
ant has previously been reported exclusively in individuals of European descent with an allele
frequency of 0.02% [12].
Initial manifestation and clinical course of disease
The phenotypic profile is summarized in Table 1, for details refer to S1 Table. Renal disease
manifested at median age 4.5 (range: 1.4–17.2) years. 69% of patients presented with nephrotic
range proteinuria. Advanced chronic kidney disease (CKD stage 4–5) was present in only two
individuals at the time of diagnosis. The two affected siblings identified by family screening
exhibited asymptomatic proteinuria. Microscopic hematuria was present in only one patient at
disease onset. Focal segmental glomerulosclerosis (FSGS) was found in 82% of biopsies,
including three differentiated as collapsing and one as hilar lesion subtypes. The remaining
cases were classified as minimal change disease (n = 5). Immunosuppressive therapy was ini-
tially applied in 26 out of 33 cases with available treatment information (all unsuspectedly
diagnosed and 15 of 21 cases with syndromic phenotype). All patients were resistant to oral
steroid therapy. In eight patients initial transient partial responsiveness to calcineurin inhibi-
tors was documented, however the disease inevitably progressed to ESRD within 6 years from
diagnosis (median age at ESKD 8.7 (IQR 5.6–10.0) yrs).
Renal failure progressed more rapidly than in patients with podocin nephropathy, the most
common hereditary podocytopathy. Median ESKD-free survival time was 8.7 (95% CI 8.0–9.4)
Fig 1. Localization of SMARCAL1 mutations detected in 34 subjects with Schimke immuno-osseous
dysplasia. Legend: Tagged ðblack frameÞ : recurrent mutations detected in at least three unrelated patients;
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years for SMARCAL1 vs. 13.0 (95%CI 11.8–14.1) years for NPHS2 nephropathy (p = 0.013)
(Fig 2).
Short stature was present in 31/34 patients at time of diagnosis and growth failure was uni-
versally observed during a mean follow-up time of 4.7 years (Fig 3). Growth retardation had
already been evident in utero in 96%, and 61% were born prematurely. Growth hormone ther-
apy, administered in 7 children, was largely ineffective.
83% of patients had hematological abnormalities, the most common being low T cell
counts. Two patients developed post-transplant lymphoproliferative disease, two ITP (immune
thrombocytopenic purpura), one patient Evans syndrome, and one acute disseminated
encephalomyelitis. Eleven patients had recurrent respiratory infections, and six developed
severe infections (sepsis, meningitis). 50% of patients had mild to moderate hypothyroidism.
Six patients had restrictive lung disease necessitating oxygen therapy. Cerebral ischemic events
were reported in 13 (39%) patients with subsequent epilepsy in eleven. Six patients (18%) had
moderate cognitive impairment and another three presented with mild developmental delay.
Table 1. Phenotypic features of patients with Schimke immuno-osseous dysplasia (n = 34).
Entire cohort Patients diagnosed by phenotype Patients diagnosed by genetic screeninga
N (females) 34 (14) 23 (6) 11 (8)*
Genotype
Bi-allelic truncating mutationb 32.4% (11/34) 47.8% (11/23) 0*
Bi-allelic missense mutation 35.3% (12/34) 21.7% (5/23) 63.6% (7/11)*
Other 35.3% (11/34) 30.4% (7/23) 36.4% (4/11)
Median age at diagnosis (IQR) [years] 4.5 (3.2–7.2) 4.1 (3.0–6.8) 5.7 (4.8–8.4)
Nephrotic range proteinuria at diagnosis 69.0% 66.7% 72.7%
Histopathological findings
FSGS 81.5% (22/27) 87.5% (14/16) 72.7% (8/11)
MCN 18.5% (5/27) 12.5% (2/16) 27.3% (3/11)
Median age at ESKD (IQR) [years] 8.7 (5.6–10.0) 8.9 (5.6–11.8) 8.7 (6.1–8.9)
Patient survival at age 10 yrs 53.6 ±9.7% 40.4 ± 11.0% 87.5 ± 11.7%*
Intrauterine growth retardation 96.4% (27/28) 100% (20/20) 87.5% (7/8)
Preterm delivery 60.7% (17/28) 70.0% (14/20) 37.5% (3/8)
Height SDS at diagnosis -3.30 ± 1.46 -3.40 ± 1.46 -3.22 ± 1.50
Height SDS at last observation -5.24 ± 1.84 -5.81 ± 1.76 -3.81 ± 1.18 **
Lymphocyte abnormalities 83.3% (25/30) 82.6% (19/23) 85.7% (6/7)
Recurrent and/or severe infections 54.8% (17/31) 75.0% (15/20) 18.2% (2/11)*
Abnormal thyroid function 50.0% (15/30) 52.4% (11/21) 44.4% (4/9)
Cerebral ischemic events 39.4% (13/33) 45.5% (10/22) 27.3% (3/11)
Seizures 32.4% (11/34) 34.8% (8/23) 27.3% (3/11)
Cognitive impairment, developmental delay 26.5% (9/34) 34.8% (8/23) 9.1% (1/11)
Lymphoproliferative disorder 8.8% (3/34) 13.6% (3/22) 0
Autoimmune disorders 8.8% (3/34) 8.7% (2/23) 9.1% (1/11)
a9 SRNS patients detected incidentally to harbor SMARCAL1 biallelic mutation through multigenic mutational screening and 2 additional cases of siblings
from two families subsequently identified through family testing.
bNonsense, frame-shift, splice-site, large deletion (of the entire gene).
*p<0.05,
**p<0.005.
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Overall patient survival rate at age 10 years was 54±10%. Six patients died while on conser-
vative treatment, two on dialysis and four post-transplant. The most common causes of death
were severe infections (n = 7) and cerebral events (n = 4).
Characteristics of patients diagnosed incidentally through NGS
screening
The patients diagnosed unexpectedly by NGS screening showed a milder extrarenal phenotype
during follow-up (Table 1), including less frequent infections and no episodes of sepsis, a
tendency for less common and less severe cerebral ischemic events, and almost 50% better
10-year patient survival compared to the patients in whom the diagnosis was prompted by the
presence of syndromic features (Fig 4). In contrast to their milder extrarenal symptoms the
incidentally diagnosed children did not differ from those diagnosed by phenotype with regards
Fig 2. Age at attainment of ESKD in 34 patients with SMARCAL1 glomerulopathy vs. 156 cases of
NPHS2-associated SRNS from PodoNet Registry [4].
https://doi.org/10.1371/journal.pone.0180926.g002
SMARCAL1-related glomerulopathy
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to the timing of onset of proteinuria and the rate of progression to ESKD (Fig 4). Importantly
in this context, 10 of the 11 incidentally diagnosed patients were small for age when SRNS was
first diagnosed and renal function was still normal.
Genotype-phenotype correlation analysis
Genotype-phenotype correlation analysis of our cohort revealed that 11 patients with bi-allelic
truncating (nonsense, frameshift, splice-site or entire gene deletion) mutations exhibited the
most severe, and 12 patients with bi-allelic missense mutations the most benign phenotype.
Exceptions to this rule were the C-terminal mutations c.2244+5G>A, c.2207delT, and
c.2542G>T (p.Glu848), which were associated with a relatively mild phenotype limited to
dysmorphy, skeletal features and renal disease. Patients with bi-allelic truncating mutations
exhibited higher mortality than children with bi-allelic missense variants, with 25±15% vs.
67±16% 10-year survival respectively (p = 0.04, S2 Fig). The renal phenotypes did not differ
between these groups of genotypes with otherwise high and low respective risk for a severe
phenotype, with a similar median age at attainment of ESRD 8.6±1.4 vs. 8.7±1.6 years; p = n.s,
S2 Fig).
Fig 3. Progressive growth failure in children with Schimke immuno-osseous dysplasia.
https://doi.org/10.1371/journal.pone.0180926.g003
SMARCAL1-related glomerulopathy
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Discussion
SMARCAL1, the gene defective in SIOD, plays an important role in DNA stabilization and its
deficiency leads to impairment of cellular functions due to progressive DNA damage. This
results in a progressive systemic disease with early mortality. However, the extent of clinical
symptoms and rate of functional deterioration vary to some degree, with some patients mani-
festing in later childhood and surviving into adulthood [2,13]. Previous reports analyzed
cohorts of SIOD patients diagnosed based on their syndromic phenotype, and did not assess
the evolution of renal function in detail [1,2,11,13–16]. In this study, we started out from a reg-
istry of childhood-onset steroid resistant nephrotic syndrome incorporating SIOD patients
diagnosed either on clinical grounds or by comprehensive gene panel screening. We observed
a wide and highly variable spectrum of extrarenal symptoms, most of which only emerged
over time. Age at diagnosis ranged from 1 to 17 years, and the diagnosis was made unexpect-
edly by SRNS-gene panel screening in one third of cases. Ninety percent of the incidentally
diagnosed children survived to adolescent and adult age, as compared to only 45% of those
diagnosed by the classical clinical phenotype. The only invariable extrarenal disease manifesta-
tion was short stature, in almost all cases manifesting already at birth with smallness for gesta-
tional age and progressing in severity over time. Although growth failure was slightly less
severe in the subgroup diagnosed unexpectedly by NGS screening, this observation allows the
important clinical conclusion that small stature at the time of diagnosis in a child with other-
wise isolated SRNS, in particular when combined with a history of intrauterine growth retar-
dation, is a strong diagnostic clue to SIOD.
Fig 4. Patient survival (left) and ESKD-free survival rate (right) of patients with Schimke immunoosseous dysplasia diagnosed based on
phenotype vs. patients diagnosed incidentally through SRNS-panel gene testing. Patients who deceased before reaching ESKD were censored
in the renal survival analysis.
https://doi.org/10.1371/journal.pone.0180926.g004
SMARCAL1-related glomerulopathy
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Disease severity in SIOD appears inversely proportionate to overall residual SMARCAL1
activity [15], although substantial phenotypic variation was noted among patients carrying the
same mutation even within families [1,16]. Lou et al. proposed that infantile-onset, early lethal
SIOD would result from presence of at least one SMARCAL1 null allele (deletion, nonsense, or
frameshift mutation), whereas a juvenile form with less severe phenotype and survival into the
second and third decade of life would arise from missense mutations [13,15]. Molecular work
has demonstrated that truncating mutations indeed usually cause a loss of SMARCAL1 mRNA
and protein, whereas missense mutations alter protein stability, subcellular localisation, chro-
matin binding and enzymatic activity [15]. In the cohort presented here bi-allelic truncating
mutations indeed exhibited a more severe clinical phenotype than patients with bi-allelic mis-
sense variants, with a more than twofold difference in 10-year patient survival. However,
approximately 50% of SIOD cases are compound heterozygous; in these families genotype-
phenotype correlations are not as straightforward. Adding further complexity, we observed
that truncating alleles affecting only the C-terminal fragment of the protein appear to associate
with a less severe phenotype whereas all but one missense mutations affecting the crucial N-
terminal helicase ATP-ase catalytic subdomain caused a clear SIOD phenotype. Hence, the
intragenic localization of the lesion needs to be taken into account when inferring from the
genotype to the likely phenotype.
SMARCAL1 is expressed in all renal cell lineages during kidney development, and in some
but not all glomerular endothelial cells and podocytes, tubular epithelial and collecting duct
cells of the mature human kidney [14]. Renal cells of SIOD patients show increased DNA frag-
mentation [14]. Remarkably, despite ubiquitous expression of the defective gene from earliest
stages of kidney development the renal phenotype is initially limited to a proteinuric glomeru-
lopathy manifesting years after birth, usually with FSGS or even minimal change disease histo-
pathology and normal GFR at time of diagnosis in the vast majority of patients.
The diagnosis of asymptomatic proteinuria in two affected siblings detected by family
screening suggests that glomerular dysfunction probably develops gradually over time. While
relatively slow in onset, once manifest the nephropathy inevitably progresses to end-stage kid-
ney disease. We observed the progression of renal failure in SIOD to be more rapid than in chil-
dren with podocin nephropathy, the most common form of recessive hereditary SRNS. We
speculate that the more aggressive course of renal failure in patients with SMARCAL1-associated
disease relative to podocin deficiency—which exclusively affects the podocyte—may be related
to additional functional effects of defective SMARCAL1 expressed in other nephron structures.
Most notably, in striking contrast to the extrarenal SIOD phenotype neither the onset nor
the course of renal disease exhibited any correlation with the type of genetic lesion. Patients
with bi-allelic missense mutations did not differ in renal survival from those with bi-allelic
truncating mutations. Likewise, the renal prognosis was equally poor in patients diagnosed
incidentally by gene panel screening and in those who were diagnosed on clinical grounds by
their syndromic phenotype. This unexpected finding indicates a high sensitivity of the renal
tissues to the cumulative effects of genomic instability. We speculate that the podocyte, as a
post-mitotic cell type, may be particularly vulnerable to this pathogenic mechanism since dys-
functional cells cannot be replaced by proliferation of less affected cells. As a consequence,
even minor genetic lesions with retained residual enzymatic activity would lead to progressive
loss of the glomerular filtration barrier and progressive proteinuria-related renal damage.
Conclusions
In conclusion, our study demonstrates that a considerable fraction of patients with SRNS due
to SIOD is oligosymptomatic, presenting only with proteinuria and short stature. Whereas
SMARCAL1-related glomerulopathy
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extrarenal symptoms and patient survival vary widely and correlate with the type of genetic
abnormality, the proteinuric glomerulopathy invariably progresses to end-stage kidney disease
within the first two decades of life. It can be expected that the detection rate of milder SIOD
variants will increase with routine NGS gene panel screening. SMARCAL1 should be included
in SRNS/FSGS gene panels.
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